410957
3-Isobutyl-1-methylxanthine
≥98% (HPLC), solid, cAMP and cGMP phosphodiesterase inhibitor, Calbiochem®
Sinónimos:
3-Isobutyl-1-methylxanthine, IBMX
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C10H14N4O2
Número CAS:
Peso molecular:
222.24
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
3-Isobutyl-1-methylxanthine, A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM).
Quality Level
description
RTECS - ZD8500000
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
ethanol: 10 mg/mL, DMSO: 100 mM, methanol: 50 mg/mL
shipped in
ambient
storage temp.
−20°C
SMILES string
[n]1(c2nc[nH]c2[c]([n]([c]1=O)C)=O)CC(C)C
InChI
1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
InChI key
APIXJSLKIYYUKG-UHFFFAOYSA-N
General description
A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM). Also acts as an adenosine receptor antagonist. Reported to inhibit TNF-α expression in adipocyte precursor cells.
A non-specific, cell-permeable inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM). Also acts as an adenosine receptor antagonist. Reported to inhibit TNFα expression in adipocyte precursor cells.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
cAMP and cGMP phosphodiesterases
cAMP and cGMP phosphodiesterases
Product does not compete with ATP.
Reversible: no
Target IC50: 2-50 µM against cAMP and cGMP phosphodiesterases
Preparation Note
Following reconstitution in ethanol or methanol, refrigerate (4°C). Following reconstitution in DMSO, aliquot and freeze (-20°C). Ethanol/methanol and DMSO stock solutions are stable for up to 6 months at 4°C or -20°C, respectively.
Heating may be required to achieve complete solubilization.
Other Notes
Hube, F., et al. 1999. Horm. Metab. Res.31, 359.
Morgan, A.J., et al. 1993. Biochem. Pharmacol.45, 2373.
Scamps, F., et al. 1993. Eur. J. Pharmacol. 244, 119.
Turner, N.C., et al. 1993. Br. J. Pharmacol. 108, 876.
Tamura, T., et al. 1991. J. Gen. Physiol. 98, 95.
Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150.
Russell, T.R. 1979. Proc. Natl. Acad. Sci. USA76, 4451.
Morgan, A.J., et al. 1993. Biochem. Pharmacol.45, 2373.
Scamps, F., et al. 1993. Eur. J. Pharmacol. 244, 119.
Turner, N.C., et al. 1993. Br. J. Pharmacol. 108, 876.
Tamura, T., et al. 1991. J. Gen. Physiol. 98, 95.
Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150.
Russell, T.R. 1979. Proc. Natl. Acad. Sci. USA76, 4451.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Jiang Li et al.
Antioxidants (Basel, Switzerland), 13(5) (2024-05-25)
Hypertension reduces the bioavailability of vascular nitric oxide (NO) and contributes to the onset of vascular dementia (VaD). A loss of NO bioavailability increases inflammation and oxidative stress. 2-(4-Methylthiazol-5-yl) ethyl nitrate hydrochloride (W1302) is a novel nitric oxide donor (NOD)
Jiankun Xu et al.
Bioactive materials, 8, 95-108 (2021-09-21)
Magnesium metal and its alloys are being developed as effective orthopedic implants; however, the mechanisms underlying the actions of magnesium on bones remain unclear. Cystic fibrosis, the most common genetic disease in Caucasians caused by the mutation of CFTR, has
H Ji
Methods in molecular medicine, 51, 363-377 (2001-01-01)
Angiotensin type-1 receptors (AT(1) receptors) mediate various physiological actions of angiotensin (Ang II) via multiple-signal transduction pathways (1). In addition to the phospholipase C pathway and dihydropyridine-sensitive voltage-dependent calcium channels, AT(1) receptors can couple to inhibition of adenylate cyclase via